Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency

Intern Med. 2018 Jul 15;57(14):2025-2028. doi: 10.2169/internalmedicine.0483-17. Epub 2018 Mar 9.

Abstract

A 19-year-old man was referred due to sudden onset of right foot pain and chest discomfort. Contrast-enhanced computed tomography revealed massive thrombi in the right pulmonary artery and femoral vein. The patient's father had experienced multiple recurrences of venous thromboembolism (VTE) and was diagnosed with inherited antithrombin deficiency by a genetic examination. The patient was administered the oral factor Xa inhibitor rivaroxaban (30 mg). After seven days, the thrombus disappeared. Rivaroxaban (15 mg) was continued for 6 months with no recurrence, indicating the efficacy of this factor Xa inhibitor for the treatment and prevention of VTE in patients with antithrombin deficiency.

Keywords: antithrombin deficiency; factor Xa inhibitor; venous thromboembolism.

Publication types

  • Case Reports

MeSH terms

  • Antithrombin III Deficiency / complications*
  • Factor Xa Inhibitors / administration & dosage
  • Factor Xa Inhibitors / therapeutic use*
  • Humans
  • Male
  • Recurrence
  • Rivaroxaban / therapeutic use
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / etiology*
  • Young Adult

Substances

  • Factor Xa Inhibitors
  • Rivaroxaban